Stocks · News reference

Mizuho Initiates Coverage On Zentalis Pharmaceuticals with Outperform Rating, Announces Price Target of $8

Jul 17, 2026, 11:23 AMBenzinga Newsdesk

Mizuho analyst Graig Suvannavejh initiates coverage on Zentalis Pharmaceuticals (NASDAQ:ZNTL) with a Outperform rating and announces Price Target of $8.

More stocks news Connected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

ZNTL

Source: benzinga
Observed: Jul 17, 2026, 11:23 AM
Checked: Jul 17, 2026, 11:23 AM
Cadence: Captured once, then retained as an archive reference
Status: fresh

Keep reading

BenzingaAug 20, 2026, 8:53 AMAvi Kapoor
Why Webull Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket
Webull Corp (NASDAQ: BULL) rose sharply in pre-market trading after reporting better-than-expected Q2 results. Revenue of $198.83M beat estimates, while adjusted EPS of $0.05 also beat.
AZI BEEM BIVI BTCT BULL
BenzingaAug 14, 2026, 1:12 PMBenzinga Newsdesk
Zentalis Pharmaceuticals shares are trading lower after the company announced the pricing of its $80.5 million proposed public offering of 23 million shares at $3.50 per share.
ZNTL
BenzingaAug 14, 2026, 12:06 PMBenzinga Insights
12 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers Capricor Therapeutics (NASDAQ:CAPR) stock rose 94.8% to $8.2 during Friday's pre-market session. The company's market cap stands at $243.8 million. As per the news, the Q2 earnings report came out
AKAN BYSI CAPR CBUS ETON
BenzingaAug 14, 2026, 5:08 AMBenzinga Newsdesk
Reported Earlier, Zentalis Pharmaceuticals Prices Underwritten Public Offering Of 23M Shares At $3.50 Per Share, Expects $80.5M Gross Proceeds
ZNTL

Mizuho Initiates Coverage On Zentalis Pharmaceuticals with Outperform Rating, Announces Price Target of $8

Connected Markets

Related Headlines

Why Webull Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket

Zentalis Pharmaceuticals shares are trading lower after the company announced the pricing of its $80.5 million proposed public offering of 23 million shares at $3.50 per share.

12 Health Care Stocks Moving In Friday's Pre-Market Session

Reported Earlier, Zentalis Pharmaceuticals Prices Underwritten Public Offering Of 23M Shares At $3.50 Per Share, Expects $80.5M Gross Proceeds